Literature DB >> 19809954

[Are there gender-related differences in the therapeutic management of patients suffering from inflammatory bowel disease? Subgroup analysis of a prospective multicentre online-based trial].

I Blumenstein1, H Bock, C Zosel, A U Dignass, F Hartmann, S Zeuzem, J M Stein, O Schroeder.   

Abstract

INTRODUCTION: The most frequently prescribed medications for patients suffering from inflammatory bowel disease (IBD) in the Rhein-Main region of Germany are aminosalicylates and corticosteroids irrespective of the disease activity. In contrast, immunomodulators only play a marginal role. As anti-TNF therapy is very costly, it is prescribed in outpatient services of hospitals rather than in gastroenterological practices. AIM: The aim of this study was to evaluate possible gender-related differences in the therapeutic management of IBD patients treated in the Rhein-Main region of Germany.
METHODS: Data records about past medical history, disease status, laboratory values and medical treatment of outpatients of 10 gastroenterological practices and 3 hospitals were collected from November 1st 2005 to July 31st 2007 and analysed with regard to gender-related differences in therapy and disease management.
RESULTS: Overall, no statistically significant difference in gender-specific medical treatment could be observed in the study cohort. However, detailed analyses revealed, that 1. women suffering from IBD, who are treated in outpatient services of hospitals, are more often under immunosuppressants, irrespective of disease activity, 2. in gastroenterological practices less than 3 % of patients are prescribed any immunosuppressive therapy (vs. 17 % [men] und 42 % [women] in hospital outpatient services), and 3. anti-TNF therapy is applied more frequently in men as compared to women in hospital outpatient services in both remission and active disease.
CONCLUSION: This study discloses the gender-specific differences in the therapeutic management of IBD patients in a congested urban area in Germany. Further studies are required to confirm the tendencies detected. Copyright Georg Thieme Verlag KG Stuttgart . New York.

Entities:  

Mesh:

Year:  2009        PMID: 19809954     DOI: 10.1055/s-0028-1109647

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  4 in total

Review 1.  Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease.

Authors:  Wendy A Goodman; Ian P Erkkila; Theresa T Pizarro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-09-08       Impact factor: 46.802

2.  Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice-results of a non-representative survey.

Authors:  Lea I Kredel; Oliver Schneidereit; Jörg C Hoffmann; Britta Siegmund; Jan C Preiß
Journal:  Int J Colorectal Dis       Date:  2018-12-07       Impact factor: 2.571

3.  Risk factors and prognostic value of acute severe lower gastrointestinal bleeding in Crohn's disease.

Authors:  Jiyoung Yoon; Dae Sung Kim; Ye-Jee Kim; Jin Wook Lee; Seung Wook Hong; Ha Won Hwang; Sung Wook Hwang; Sang Hyoung Park; Dong-Hoon Yang; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang
Journal:  World J Gastroenterol       Date:  2021-05-21       Impact factor: 5.742

4.  Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study.

Authors:  Nienke Lesuis; Ragnar Befrits; Filippa Nyberg; Ronald F van Vollenhoven
Journal:  BMC Med       Date:  2012-08-01       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.